The total 1-year survival in the LA-treated group was 61.5% in FLT3 mut AML patients, whereas none of the FLT3 wt AML patients presenting with hyperleukocytosis receiving LA survived up to one year after initial diagnosis. This evidence concerns the gene FLT3 and acute myeloid leukemia.